Overall, our observation provides a novel insight that afatinib improves the therapeutic efficacy of radiotherapy via manipulating the activity of the CD44-Stat3 axis and EMT process in NPC cells, besides its intrinsic effects in inhibiting EGFR and HER2. The gene discussed is CD44; the disease is nasopharyngeal carcinoma.